Learn about our comprehensive antibody validation methods to ensure monospecificity.  Antibody Validation>>

CLPS Antibodies

Colipase is a protein encoded by the CLPS gene on chromosome 6p21.1. Translation of the gene produces an 89 amino acid protein with a molecular weight of approximately 10 kDa. Post-translational modifications of colipase include phosphorylation and glycosylation. CLPS is primarily an intracellular protein, specifically localized in the pancreas.

Colipase is predominantly expressed in the pancreas, specifically in pancreatic acinar cells. It is synthesized and secreted into the duodenum along with pancreatic lipase, where it plays a crucial role in the digestion and absorption of dietary fats. Colipase acts as a cofactor for pancreatic lipase, binding to the lipid-water interface and stabilizing the enzyme, thus enabling it to efficiently hydrolyze triglycerides into free fatty acids and monoglycerides for absorption in the small intestine. Various factors regulate its expression, including hormonal signals such as cholecystokinin and dietary fat intake. Dysfunction or deficiency of colipase can impair fat digestion and absorption, leading to malabsorption syndromes such as pancreatic exocrine insufficiency or steatorrhea. In these conditions, inadequate secretion or activity of colipase results in decreased lipid digestion and absorption, leading to nutritional deficiencies and gastrointestinal symptoms.

Therapeutic strategies for pancreatic exocrine insufficiency may include supplementation with exogenous colipase or pancreatic enzyme replacement therapy (PERT) containing colipase along with pancreatic lipase and other digestive enzymes. PERT has been shown to improve fat absorption and alleviate symptoms in patients with this condition. While there are currently no reported examples of immunotherapy specifically targeting colipase, ongoing research into pancreatic disorders and fat malabsorption may lead to the development of novel therapeutic approaches aimed at modulating colipase activity for therapeutic benefit.

NeoBiotechnologies offers a variety of antibodies against colipase that have been validated for immunohistochemistry and Western blotting. Additionally, we hold exclusive rights to colipase antibodies available for licensing or collaboration [https://www.neobiotechnologies.com/shop/?s=CLPS].


Colipase, COL_HUMAN; Colipase; Colipase pancreatic; Pancreatic colipase preproprotein

Research Areas


Showing all 8 results


Showing all 8 results


We hold Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.